Traded as NASDAQ: EXEL Website www.exelixis.com | ||
 | ||
Key people Michael Morrissey, President, Research and DevelopmentFrank Karbe, CFOGisela M. Schwab, Executive Vice President and Chief Medical OfficerPamela A. Simonton, Executive Vice President and General CounselPeter Lamb, Senior Vice President, Discovery Research and Chief Scientific OfficerLupe M. Rivera, Senior Vice President, Operations Stock price EXEL (NASDAQ) US$ 21.60 -0.40 (-1.82%)10 Mar, 11:46 AM GMT-5 - Disclaimer Headquarters South San Francisco, California, United States Founded 15 November 1994, Cambridge, Massachusetts, United States Motto A Better Way to Better Medicine Founders Stelios Papadopoulos, Corey S. Goodman Subsidiaries X Ceptor Therapeutics Inc, Exelixis Plant Sciences, Inc, Exelixis Patent Company, LLC | ||
Exelixis designer company portfolio
Exelixis is a genomics-based drug discovery company located in South San Francisco, Ca., and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. It works on the development of anti-cancer therapies. Exelixis has several compounds in various stages of FDA approval including :
The company also has various compounds in phase 1 clinical trials, including
Its lead compound, XL184, has been approved for treatment of medullary thyroid cancer and is currently in a number of clinical trials for prostate, ovarian, brain, melanoma, breast, non-small cell lung, hepatocellular, kidney. During its trial for the treatment of medullary thyroid cancer, XL184 was designated orphan drug status by the FDA and given the generic name, cabozantinib. Cabozantinib is an inhibitor of the tyrosine kinases Met and VEGFR2, and has been shown to abrogate tumor growth, metastasis, and angiogenesis.